Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EPS (Basic) (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of EPS (Basic) readings, the most recent being -$0.14 for Q1 2026.

  • On a quarterly basis, EPS (Basic) rose 71.43% to -$0.14 in Q1 2026 year-over-year; TTM through Mar 2026 was -$1.29, a 21.34% increase, with the full-year FY2025 number at -$1.64, down 5.81% from a year prior.
  • EPS (Basic) hit -$0.14 in Q1 2026 for Barinthus Biotherapeutics, up from -$0.27 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.42 in Q2 2022 to a low of -$0.62 in Q2 2023.
  • Median EPS (Basic) over the past 5 years was -$0.4 (2024), compared with a mean of -$0.3.
  • Biggest five-year swings in EPS (Basic): skyrocketed 269.23% in 2022 and later tumbled 785.71% in 2023.
  • Barinthus Biotherapeutics' EPS (Basic) stood at -$0.57 in 2022, then increased by 21.05% to -$0.45 in 2023, then dropped by 13.33% to -$0.51 in 2024, then skyrocketed by 47.06% to -$0.27 in 2025, then skyrocketed by 48.15% to -$0.14 in 2026.
  • The last three reported values for EPS (Basic) were -$0.14 (Q1 2026), -$0.27 (Q4 2025), and -$0.36 (Q3 2025) per Business Quant data.